21269-85-2

Usage

Uses

Used in Medicinal Chemistry:
Pyrido[1,2-a]benzimidazol-4-ol, 1,2,3,4-tetrahydro(8CI,9CI) is used as a compound in medicinal chemistry for its potential to contribute to the development of new drugs. Its unique structure may allow for specific interactions with biological targets, offering opportunities for the treatment of various diseases and conditions.
Used in Drug Development:
In the field of drug development, Pyrido[1,2-a]benzimidazol-4-ol, 1,2,3,4-tetrahydro(8CI,9CI) is utilized as a starting material or a building block for the synthesis of more complex molecules with therapeutic potential. Its heterocyclic nature may provide a foundation for the creation of novel pharmaceutical agents.
Further research is necessary to determine the specific properties and potential uses of Pyrido[1,2-a]benzimidazol-4-ol, 1,2,3,4-tetrahydroin various fields of science and technology, including but not limited to pharmaceuticals, materials science, and chemical biology. As our understanding of Pyrido[1,2-a]benzimidazol-4-ol, 1,2,3,4-tetrahydro- (8CI,9CI) grows, so too may its applications in these and other areas.

Upstream product

• 19018-22-5 1-allylbenzimidazole 
• 201230-82-2 carbon monoxide 
• 51-17-2 benzoimidazole 

Downstream Products

• 1609943-17-0 4-((diphenylphosphino)oxy)-1,2,3,4-tetrahydrobenzimidazo[1,2-α]pyridine 

Relevant academic research and scientific papers

Development of a Benzimidazole-Derived Bidentate P,N-Ligand for Enantioselective Iridium-Catalyzed Hydrogenations

The development of a novel benzimidazole-derived bidentate P,N-ligand and its application in Ir-catalyzed hydrogenation is described. The ligand backbone was obtained through a one-pot tandem hydroformylation-cyclization sequence and the enantiomers of the generated alcohol were separated by chiral HPLC. By comparing the experimentally obtained CD spectra of the enantiomers with the simulated spectra generated from time-dependent DFT calculations, the absolute configuration could be obtained. The chiral alcohols could further be isolated on a larger scale after transesterification by using Candida Antarctica lipase B (Novozym 435) and could subsequently be converted into the corresponding chiral P,N-ligand by reaction with ClPPh2. The coordination properties of the racemic P,N-ligand were investigated and the molecular structure of the RhI complex [(P,N)Rh(CO)Cl] was determined by X-ray crystal structure analysis. The corresponding chiral cationic IrI complex was used as catalyst for the enantioselective hydrogenation of prochiral N-phenyl-(1-phenylethylidene)amine and trans-α-methylstilbene. For the N-aryl-substituted imine, enantiomeric excesses of only 10 % were obtained, whereas the unfunctionalized olefin could be hydrogenated with enantiomeric excesses of up to 90 %. Interestingly, the modular synthetic access to the P,N-hybrid system described here allows facile modification of the ligand structure, which should extend the scope of such novel P,N-ligands for asymmetric catalytic conversions to a large extent in the future.

Development of a benzimidazole-derived bidentate P,N-ligand for enantioselective iridium-catalyzed hydrogenations

The development of a novel benzimidazole-derived bidentate P,N-ligand and its application in Ir-catalyzed hydrogenation is described. The ligand backbone was obtained through a one-pot tandem hydroformylation-cyclization sequence and the enantiomers of the generated alcohol were separated by chiral HPLC. By comparing the experimentally obtained CD spectra of the enantiomers with the simulated spectra generated from time-dependent DFT calculations, the absolute configuration could be obtained. The chiral alcohols could further be isolated on a larger scale after transesterification by using Candida Antarctica lipase B (Novozym 435) and could subsequently be converted into the corresponding chiral P,N-ligand by reaction with ClPPh2. The coordination properties of the racemic P,N-ligand were investigated and the molecular structure of the RhI complex [(P,N)Rh(CO)Cl] was determined by X-ray crystal structure analysis. The corresponding chiral cationic IrI complex was used as catalyst for the enantioselective hydrogenation of prochiral N-phenyl-(1-phenylethylidene)amine and trans-α-methylstilbene. For the N-aryl-substituted imine, enantiomeric excesses of only 10 % were obtained, whereas the unfunctionalized olefin could be hydrogenated with enantiomeric excesses of up to 90 %. Interestingly, the modular synthetic access to the P,N-hybrid system described here allows facile modification of the ligand structure, which should extend the scope of such novel P,N-ligands for asymmetric catalytic conversions to a large extent in the future. We report on the development of a novel bidentate P,N-ligand with a benzimidazole-based backbone obtained through a one-pot tandem hydroformylation-cyclization reaction. The chiral ligand was successfully applied in Ir-catalyzed hydrogenation reactions in which enantiomeric excesses of up to 90 % could be obtained. Copyright